Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer

详细信息    查看全文

• 作者：Gillian M. Keating
• 刊名：Drugs
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：75
• 期：16
• 页码：1925-1934
• 全文大小：558 KB
• 参考文献：1.Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27-9.
  2.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (version 7.2015). 2015. http://?www.?nccn.?org/-/span> . Accessed 12 Oct 2015.
  3.Zielinski C, Knapp S, Mascaux C, et al. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol. 2013;24(5):1170-.PubMedCentral CrossRef PubMed
  4.Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846-6.CrossRef PubMed
  5.Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-4.PubMedCentral CrossRef PubMed
  6.Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421-.PubMedCentral CrossRef PubMed
  7.Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11(9):1307-6.CrossRef PubMed
  8.Bristol-Myers Squibb Company. Opdivo (nivolumab) injection, for intravenous use: US prescribing information. 2015. http://?packageinserts.?bms.?com/?pi/?pi_?opdivo.?pdf . Accessed 12 Oct 2015.
  9.European Medicines Agency. Nivolumab BMS: EU summary of product characteristics. 2015. http://?www.?ema.?europa.?eu . Accessed 12 Oct 2015.
  10.European Medicines Agency. Opdivo (nivolumab): EU summary of product characteristics. 2015. http://?www.?ema.?europa.?eu . Accessed 12 Oct 2015.
  11.Food and Drug Administration. FDA expands approved use of Opdivo in advanced lung cancer. 2015. http://?www.?fda.?gov/?NewsEvents/?Newsroom/?PressAnnouncemen?ts/?ucm466413.?htm . Accessed 12 Oct 2015.
  12.Berman D, Korman A, Peck R, et al. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther. 2015;148:132-3.CrossRef PubMed
  13.Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-5.CrossRef PubMed
  14.Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-4.PubMedCentral CrossRef PubMed
  15.Brahmer J. Treatment targeting PD1/PDL1 and toxicity [abstract no. MS09.2]. J Thorac Oncol. 2013;8(Suppl 2):S53-.
  16.Passey C, Simon J, Roy A, et al. Assessment of drug interaction potential by nivolumab using cytokine modulation data [abstract no. 118 plus poster]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. 2015.
  17.Agrawal S, Williams D, Waxman I, et al. Absence of QT prolongation effect by nivolumab or ipilimumab in patients with solid tumors [abstract no. 117 plus poster]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. 2015.
  18.Feng Y, Bajaj G, Wang X, et al. Model-based analysis of nivolumab to support clinical pharmacology profiling in subjects with solid tumors [abstract]. Clin Pharmacol Ther. 2015;97(Suppl 1):S41-.
  19.Agrawal S, Feng Y, Kollia G, et al. Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody [abstract no. TPS2622]. J Clin Oncol. 2012;30(15 Suppl).
  20.Feng Y, Wang X, Agrawal S, et al. Nivolumab exposure-response (E-R) analysis for clinical development of nivolumab in advanced refractory squamous non-small cell lung cancer [abstract no. QP-19]. Clin Pharmacol Ther. 2015;97(Suppl 1):S7.
  21.Agrawal S, Roy A, Feng Y, et al. Immunogenicity of nivolumab and its impact on pharmacokinetics and safety in subjects with metastatic solid tumors [abstract no. 115 plus poster]. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. 2015.
  22.Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004-2.CrossRef PubMed
  23.Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-5.CrossRef PubMed
  24.Sakai H, Nishio M, Hida T, et al. Phase II studies of nivolumab in patients with advanced squamous (SQ) or non-squamous (NSQ) n
• 作者单位：Gillian M. Keating (1)
  
  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand
  
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1950

文摘

Nivolumab (Opdivo?; Nivolumab BMS? was the first programmed death (PD)-1 immune checkpoint inhibitor to be approved for use in advanced, squamous non-small cell lung cancer (NSCLC) following prior chemotherapy. In the pivotal CheckMate 017 trial, intravenous nivolumab 3 mg/kg every 2 weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC. Nivolumab was also better tolerated than docetaxel in CheckMate 017, and its adverse event profile (which included immune-mediated adverse events) was manageable. In conclusion, nivolumab represents an important advance in previously-treated, advanced, squamous NSCLC. The manuscript was reviewed by: J. G. Aerts, Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; C. Choua?d, Service de Pneumologie, GRC Onco Paris Est, UPEC, CHI Créteil, Créteil, France; L. Crinò, Division of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy; J. Mazières, Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, University of Toulouse III (Paul Sabatier), Toulouse, France; A. Pluzanski, Lung Cancer Department, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.